Scholarlink

<p>Hematologic malignancies, including leukemia, lymphoma, and multiple myeloma, represent a diverse group of blood cancers driven by complex oncogenic pathways and genetic aberrations. Despite advances in treatment, resistance and relapse remain significant clinical challenges. This review presents an integrative approach to blood cancer therapy, highlighting the convergence of precision medicine, CRISPR-based gene editing, immunotherapy (including CAR-T cells and immune checkpoint inhibitors), and targeted modulation of amino acid metabolism. We investigate the molecular pathways driving tumour development and resistance, highlighting how multi-omic profiling facilitates personalised therapy approaches. Recent breakthroughs in reprogramming immune responses and editing driver mutations have revolutionized therapeutic paradigms. Additionally, the metabolic dependencies of cancer cells, particularly in amino acid biosynthesis and catabolism, offer novel vulnerabilities. This meticulous synthesis outlines a framework for translational techniques that integrate molecular targeting with immunological and metabolic regulation to improve treatment effectiveness and surmount therapeutic resistance in haematologic malignancies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Deciphering and targeting oncogenic pathways through integrated approaches and amino acid metabolism in hematologic malignancies

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月16日

查看全文
  • Farhan Ikhtiar,
  • Adil Jamal,
  • Syed M. Safeer Mehdi Bokhari

摘要

Hematologic malignancies, including leukemia, lymphoma, and multiple myeloma, represent a diverse group of blood cancers driven by complex oncogenic pathways and genetic aberrations. Despite advances in treatment, resistance and relapse remain significant clinical challenges. This review presents an integrative approach to blood cancer therapy, highlighting the convergence of precision medicine, CRISPR-based gene editing, immunotherapy (including CAR-T cells and immune checkpoint inhibitors), and targeted modulation of amino acid metabolism. We investigate the molecular pathways driving tumour development and resistance, highlighting how multi-omic profiling facilitates personalised therapy approaches. Recent breakthroughs in reprogramming immune responses and editing driver mutations have revolutionized therapeutic paradigms. Additionally, the metabolic dependencies of cancer cells, particularly in amino acid biosynthesis and catabolism, offer novel vulnerabilities. This meticulous synthesis outlines a framework for translational techniques that integrate molecular targeting with immunological and metabolic regulation to improve treatment effectiveness and surmount therapeutic resistance in haematologic malignancies.